Understanding inherited and environmental risk for lymphomas and multiple myeloma
InterLymph Consortium: interrogating pleiotropy and gene by environment interactions among hematopoietic malignancies.
This project uses genetic information and environmental histories to improve how we identify people at higher risk for lymphoma and multiple myeloma.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | International Agency for Res on Cancer NIH-funded |
| Lab location | 1 site (Lyon, France) |
| Project ID | NIH-11159756 on NIH RePORTER |
What this research studies
Researchers are combining DNA and health-history information from tens of thousands of people with Hodgkin lymphoma, non‑Hodgkin lymphoma, and multiple myeloma plus many controls to find genetic differences linked to risk. They will build and test polygenic risk scores from genome‑wide data and validate those scores in an independent group of patients. The team will also look at how genetic profiles interact with chemical and other environmental exposures to understand combined effects on subtype risk. Findings aim to clarify why some people develop specific lymphoma subtypes and who may be at greater risk.
Who could benefit from this research
Good fit: Ideal participants are people diagnosed with Hodgkin lymphoma, non‑Hodgkin lymphoma, or multiple myeloma who can provide genetic samples and information about environmental exposures.
Not a fit: People without lymphoid cancers or those unwilling/unable to provide genetic or exposure information are unlikely to gain direct benefit from participating.
Why it matters
Potential benefit: If successful, this work could improve early identification of people at higher risk and help guide prevention or targeted screening strategies.
How similar studies have performed: Previous InterLymph genome‑wide studies have identified risk variants and polygenic risk approaches show promise, but applying large‑scale gene–environment interaction analyses across many lymphoma subtypes is a newer effort.
Where this research is happening
Lyon, France
- International Agency for Res on Cancer — Lyon, France (Active)
Researchers
- Principal investigator: Mckay, James Dowling — International Agency for Res on Cancer
- Study coordinator: Mckay, James Dowling
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.